PMID- 35001772
OWN - NLM
STAT- MEDLINE
DCOM- 20220316
LR  - 20220501
IS  - 1744-7607 (Electronic)
IS  - 1742-5255 (Linking)
VI  - 17
IP  - 12
DP  - 2021 Dec
TI  - Potential and real drug interactions in patients treated with abiraterone or 
      enzalutamide in clinical practice.
PG  - 1467-1473
LID - 10.1080/17425255.2021.2027908 [doi]
AB  - BACKGROUND: Abiraterone and enzalutamide, androgen receptor pathway inhibitors 
      (ARPI) for the treatment of metastatic castration-resistant prostate cancer 
      (mCRPC), are at high risk of potential drug interactions (PDIs). We aimed to 
      describe PDIs and their management, and triggered adverse events (AEs) in 
      clinical practice. METHODS: We conducted a cross-sectional study in mCRPC 
      patients who started treatment with abiraterone or enzalutamide in a university 
      hospital between August 1st, 2016 and July 31st, 2020. Lexicomp(R) was used to 
      identify and analyze PDIs, and the clinical records to assess their management 
      and the occurrence of AEs. RESULTS: We included 173 patients: 36.8% and 93.0% 
      treated with abiraterone and enzalutamide, respectively, had at least 1 PDI. 
      Globally, 6.3% of PDIs had X-risk (contraindication due to high probability of 
      AE). Treatment was modified in 9.2% of patients and 9.8% suffered AEs due to 
      PDIs. Factors associated with a higher risk of PDIs were polypharmacy (OR= 41.0, 
      p  0.003) and treatment with enzalutamide (OR= 128.26, p < 0.001). CONCLUSIONS: 
      At least two-thirds of patients treated with ARPI suffered a PDI. Overall, 
      abiraterone would have a more favorable PDI profile. Knowing these interaction 
      profiles may be helpful to develop a more efficient therapeutic follow-up and to 
      select the safest treatment.
FAU - Vicente-Valor, Juan
AU  - Vicente-Valor J
AD  - Pharmacy Department, Hospital General Universitario Gregorio Maranon, Instituto 
      de Investigacion Sanitaria Gregorio Maranon, Madrid, Spain.
FAU - Escudero-Vilaplana, Vicente
AU  - Escudero-Vilaplana V
AD  - Pharmacy Department, Hospital General Universitario Gregorio Maranon, Instituto 
      de Investigacion Sanitaria Gregorio Maranon, Madrid, Spain.
FAU - Collado-Borrell, Roberto
AU  - Collado-Borrell R
AD  - Pharmacy Department, Hospital General Universitario Gregorio Maranon, Instituto 
      de Investigacion Sanitaria Gregorio Maranon, Madrid, Spain.
FAU - Perez-Ramirez, Sara
AU  - Perez-Ramirez S
AD  - Medical Oncology Department, Hospital General Universitario Gregorio Maranon, 
      Instituto de Investigacion Sanitaria Gregorio Maranon, Madrid, Spain.
FAU - Villanueva-Bueno, Cristina
AU  - Villanueva-Bueno C
AD  - Pharmacy Department, Hospital General Universitario Gregorio Maranon, Instituto 
      de Investigacion Sanitaria Gregorio Maranon, Madrid, Spain.
FAU - Narrillos-Moraza, Alvaro
AU  - Narrillos-Moraza A
AD  - Pharmacy Department, Hospital General Universitario Gregorio Maranon, Instituto 
      de Investigacion Sanitaria Gregorio Maranon, Madrid, Spain.
FAU - Garcia-Sanchez, Sebastian
AU  - Garcia-Sanchez S
AD  - Pharmacy Department, Hospital General Universitario Gregorio Maranon, Instituto 
      de Investigacion Sanitaria Gregorio Maranon, Madrid, Spain.
FAU - Beamud-Cortes, Manel
AU  - Beamud-Cortes M
AD  - Urology Department, Hospital General Universitario Doctor Peset, Valencia, Spain.
FAU - Herranz, Ana
AU  - Herranz A
AD  - Pharmacy Department, Hospital General Universitario Gregorio Maranon, Instituto 
      de Investigacion Sanitaria Gregorio Maranon, Madrid, Spain.
FAU - Sanjurjo, Maria
AU  - Sanjurjo M
AD  - Pharmacy Department, Hospital General Universitario Gregorio Maranon, Instituto 
      de Investigacion Sanitaria Gregorio Maranon, Madrid, Spain.
LA  - eng
PT  - Journal Article
DEP - 20220121
PL  - England
TA  - Expert Opin Drug Metab Toxicol
JT  - Expert opinion on drug metabolism & toxicology
JID - 101228422
RN  - 0 (Androstenes)
RN  - 0 (Benzamides)
RN  - 0 (Nitriles)
RN  - 2010-15-3 (Phenylthiohydantoin)
RN  - 93T0T9GKNU (enzalutamide)
RN  - EM5OCB9YJ6 (Abiraterone Acetate)
RN  - G819A456D0 (abiraterone)
SB  - IM
MH  - *Abiraterone Acetate/therapeutic use
MH  - Androstenes
MH  - Benzamides
MH  - Cross-Sectional Studies
MH  - Drug Interactions
MH  - Humans
MH  - Male
MH  - Nitriles/therapeutic use
MH  - Phenylthiohydantoin
MH  - *Prostatic Neoplasms, Castration-Resistant/drug therapy/pathology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Cancer outpatients
OT  - abiraterone
OT  - drug interactions
OT  - enzalutamide
OT  - prostate cancer
OT  - safety
EDAT- 2022/01/11 06:00
MHDA- 2022/03/17 06:00
CRDT- 2022/01/10 08:51
PHST- 2022/01/11 06:00 [pubmed]
PHST- 2022/03/17 06:00 [medline]
PHST- 2022/01/10 08:51 [entrez]
AID - 10.1080/17425255.2021.2027908 [doi]
PST - ppublish
SO  - Expert Opin Drug Metab Toxicol. 2021 Dec;17(12):1467-1473. doi: 
      10.1080/17425255.2021.2027908. Epub 2022 Jan 21.